Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1993 Dec;92(6):2756–2760. doi: 10.1172/JCI116893

Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

P Carmeliet 1, J M Stassen 1, L Schoonjans 1, B Ream 1, J J van den Oord 1, M De Mol 1, R C Mulligan 1, D Collen 1
PMCID: PMC288474  PMID: 8254029

Abstract

The effects of plasminogen activator inhibitor-1 (PAI-1) gene inactivation on hemostasis, thrombosis and thrombolysis were studied in homozygous PAI-1-deficient (PAI-1-/-) mice, generated by homologous recombination in D3 embryonic stem cells. Diluted (10-fold) whole blood clots from PAI-1-/- and from PAI-1 wild type (PAI-1+/+) mice underwent limited but significantly different (P < 0.001) spontaneous lysis within 3 h (6 +/- 1 vs 3 +/- 1%, respectively). A 25-microliters 125I-fibrin-labeled normal murine plasma clot, injected into a jugular vein, was lysed for 47 +/- 5, 66 +/- 3, and 87 +/- 7% within 8 h in PAI-1+/+, heterozygous PAI-1-deficient (PAI-1+/-), and PAI-1-/- mice, respectively (P = 0.002 for PAI-1+/+ vs PAI-1-/- mice). Corresponding values after pretreatment with 0.5 mg/kg endotoxin in PAI-1+/+ and PAI-1-/- mice, were 35 +/- 5 and 91 +/- 3% within 4 h, respectively (P < 0.001). 11 out of 26 PAI-1+/+ but only 1 out of 25 PAI-1-/- mice developed venous thrombosis (P = 0.004) within 6 d after injection of 10 or 50 micrograms endotoxin in the footpad. Spontaneous bleeding or delayed rebleeding could not be documented in PAI-1-/- mice after partial amputation of the tail or of the caecum. Thus, disruption of the PAI-1 gene in mice appears to induce a mild hyperfibrinolytic state and a greater resistance to venous thrombosis but not to impair hemostasis.

Full text

PDF
2756

Images in this article

2758Image
on p.2758
2758Image
on p.2758
2759Image
on p.2759

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aillaud M. F., Juhan-Vague I., Alessi M. C., Marecal M., Vinson M. F., Arnaud C., Vague P., Collen D. Increased PA-inhibitor levels in the postoperative period--no cause-effect relation with increased cortisol. Thromb Haemost. 1985 Aug 30;54(2):466–468. [PubMed] [Google Scholar]
  2. Astrup T. Fibrinolysis: past and present, a reflection of fifty years. Semin Thromb Hemost. 1991 Jul;17(3):161–174. doi: 10.1055/s-2007-1002606. [DOI] [PubMed] [Google Scholar]
  3. Aznar J., Estellés A., Tormo G., Sapena P., Tormo V., Blanch S., España F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J. 1988 May;59(5):535–541. doi: 10.1136/hrt.59.5.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blasi F., Verde P. Urokinase-dependent cell surface proteolysis and cancer. Semin Cancer Biol. 1990 Apr;1(2):117–126. [PubMed] [Google Scholar]
  5. Carmeliet P., Kieckens L., Schoonjans L., Ream B., van Nuffelen A., Prendergast G., Cole M., Bronson R., Collen D., Mulligan R. C. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest. 1993 Dec;92(6):2746–2755. doi: 10.1172/JCI116892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Colucci M., Paramo J. A., Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest. 1985 Mar;75(3):818–824. doi: 10.1172/JCI111777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Diéval J., Nguyen G., Gross S., Delobel J., Kruithof E. K. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood. 1991 Feb 1;77(3):528–532. [PubMed] [Google Scholar]
  8. Erickson L. A., Fici G. J., Lund J. E., Boyle T. P., Polites H. G., Marotti K. R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature. 1990 Jul 5;346(6279):74–76. doi: 10.1038/346074a0. [DOI] [PubMed] [Google Scholar]
  9. Fay W. P., Shapiro A. D., Shih J. L., Schleef R. R., Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 1992 Dec 10;327(24):1729–1733. doi: 10.1056/NEJM199212103272406. [DOI] [PubMed] [Google Scholar]
  10. Gallimore M. J., Tyler H. M., Shaw J. T. The measurement of fibrinolysis in the rat. Thromb Diath Haemorrh. 1971 Oct 31;26(2):295–310. [PubMed] [Google Scholar]
  11. Hamsten A., de Faire U., Walldius G., Dahlén G., Szamosi A., Landou C., Blombäck M., Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987 Jul 4;2(8549):3–9. doi: 10.1016/s0140-6736(87)93050-9. [DOI] [PubMed] [Google Scholar]
  12. Heremans H., Dijkmans R., Sobis H., Vandekerckhove F., Billiau A. Regulation by interferons of the local inflammatory response to bacterial lipopolysaccharide. J Immunol. 1987 Jun 15;138(12):4175–4179. [PubMed] [Google Scholar]
  13. Juhan-Vague I., Alessi M. C., Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia. 1991 Jul;34(7):457–462. doi: 10.1007/BF00403280. [DOI] [PubMed] [Google Scholar]
  14. Juhan-Vague I., Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol. 1992 Jul;2(4):427–438. doi: 10.1016/1047-2797(92)90092-5. [DOI] [PubMed] [Google Scholar]
  15. Keeton M., Eguchi Y., Sawdey M., Ahn C., Loskutoff D. J. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol. 1993 Jan;142(1):59–70. [PMC free article] [PubMed] [Google Scholar]
  16. Lee M. H., Vosburgh E., Anderson K., McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood. 1993 May 1;81(9):2357–2362. [PubMed] [Google Scholar]
  17. Levi M., Biemond B. J., van Zonneveld A. J., ten Cate J. W., Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation. 1992 Jan;85(1):305–312. doi: 10.1161/01.cir.85.1.305. [DOI] [PubMed] [Google Scholar]
  18. Lupu F., Bergonzelli G. E., Heim D. A., Cousin E., Genton C. Y., Bachmann F., Kruithof E. K. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993 Jul;13(7):1090–1100. doi: 10.1161/01.atv.13.7.1090. [DOI] [PubMed] [Google Scholar]
  19. Nilsson I. M., Ljungnér H., Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res Ed) 1985 May 18;290(6480):1453–1456. doi: 10.1136/bmj.290.6480.1453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Paramo J. A., Colucci M., Collen D., van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J (Clin Res Ed) 1985 Aug 31;291(6495):573–574. doi: 10.1136/bmj.291.6495.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Quax P. H., van den Hoogen C. M., Verheijen J. H., Padro T., Zeheb R., Gelehrter T. D., van Berkel T. J., Kuiper J., Emeis J. J. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem. 1990 Sep 15;265(26):15560–15563. [PubMed] [Google Scholar]
  22. Sawdey M. S., Loskutoff D. J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest. 1991 Oct;88(4):1346–1353. doi: 10.1172/JCI115440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Schleef R. R., Higgins D. L., Pillemer E., Levitt L. J. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 1989 May;83(5):1747–1752. doi: 10.1172/JCI114076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schneiderman J., Sawdey M. S., Keeton M. R., Bordin G. M., Bernstein E. F., Dilley R. B., Loskutoff D. J. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6998–7002. doi: 10.1073/pnas.89.15.6998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sprengers E. D., Kluft C. Plasminogen activator inhibitors. Blood. 1987 Feb;69(2):381–387. [PubMed] [Google Scholar]
  26. Tomooka S., Border W. A., Marshall B. C., Noble N. A. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int. 1992 Dec;42(6):1462–1469. doi: 10.1038/ki.1992.442. [DOI] [PubMed] [Google Scholar]
  27. VERMYLEN C., DE VREKER R. A., VERSTRAETE M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). Clin Chim Acta. 1963 May;8:418–424. doi: 10.1016/0009-8981(63)90080-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES